# Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies

> **NCT00243295** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 6 (—)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** rhBMP-2/CPM

## Key facts

- **NCT ID:** NCT00243295
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 6 (—)
- **Last updated:** 2006-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243295, "Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00243295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*